ISIS' Kynamro, ongoing anti-PCSK9 trials, gastrointestinal problems & fatty liver disease dropouts, statin interaction, exclusion of those under 18 yrs old, high cost, etc... will carve up AEGR's very very small pie into a very small slice. Note that besides the threat of anti-PCSK9 approval, the anti-PCSK TRIALS alone threaten AEGR market share ... and AMGN is recruiting as we speak.
ISIS Kynamro is no competitor and is old news. The news is outdated and the drug doesn't work. It has already been proven. This one isn't even worth arguing about. Go back to arguing how there are only 300 patients in the US instead of 3,000.